Complete restriction of fluoroquinolone use to control an outbreak of Clostridium difficile infection at a community hospital

Infection Control and Hospital Epidemiology

Volumn 30, Issue 3, 2009, Pages 264-272

  Kallen, Alexander J ^a,b,f   Thompson, Angela ^a   Ristaino, Polly ^d   Chapman, Leigh ^d   Nicholson, Ainsley ^a   Sim, Bich Thuy ^a   Lessa, Fernanda ^a,b   Sharapov, Umid ^b,c   Fadden, Elaine ^d   Boehler, Richard ^d   Gould, Carolyn ^a   Limbago, Brandi ^a   Blythe, David ^e   McDonald, L Clifford ^a  

^a NATIONAL CENTER FOR PREPAREDNESS DETECTION AND CONTROL OF INFECTIOUS DISEASES   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^d St Joseph Medical Center   (United States)

^e MARYLAND DEPARTMENT OF HEALTH AND MENTAL HYGIENE   (United States)

^f NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLINDAMYCIN; IMIPENEM; LEVOFLOXACIN; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN;

ADULT; AGED; ARTICLE; BACTERIAL STRAIN; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; COMMUNITY HOSPITAL; CONTROLLED STUDY; DIARRHEA; DRUG USE; ENVIRONMENTAL FACTOR; FEMALE; HEALTH CARE FACILITIES AND SERVICES; HUMAN; INCIDENCE; INFECTION CONTROL; MAJOR CLINICAL STUDY; MALE; PULSED FIELD GEL ELECTROPHORESIS; RETROSPECTIVE STUDY;

ANTI-BACTERIAL AGENTS; CASE-CONTROL STUDIES; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COHORT STUDIES; CROSS INFECTION; DISEASE OUTBREAKS; FLUOROQUINOLONES; HUMANS; RETROSPECTIVE STUDIES;

EID: 61849140052     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/595694     Document Type: Article

References (31)

1. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Eng J Med 2005; 353:2433-2441.
2. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Eng J Med 2005; 353:2442-2449.
3. Kuijper EJ, Coignard B, Tüll P. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect 2006;12(Suppl 6):2-18.
4. Kazakova SV, Ware K, Baughman B, et al. A hospital outbreak of diarrhea due to an emerging epidemic strain of Clostridium difficile. Clin Infect Dis 2006; 166:2518-2524.
5. Centers for Disease Control and Prevention. Data and statistics about Clostridium difficile infections. Available at: http://www.cdc.gov/ ncidod/dhqp/id-Cdiff-data.html. Accessed March 10, 2008.
6. Warny M, Pepin J, Fang A, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005; 366:1079-1084.
7. Zafar AB, Gaydos LA, Furlong WB, Nguyen MH, Mennonna PA. Effectiveness of infection control program in controlling nosocomial Clostridium difficile. Am J Infect Control 1998; 26:588-593.
8. Mayfield JL, Leet T, Miller J, Mundy LM. Environmental control to reduce transmission of Clostrdium difficile. Clin Infect Dis 2000; 31:995-1000.
9. Pepin J, Saheb N, Coulombe M-A, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005; 41:1254-1260.
10. Johnson S, Samore MH, Farrow KA, et al. Epidemics of diarrhea caused by clindamycin-resistant strain of Clostrdium difficile in four hospitals. N Eng J Med 1999;341:1645-1651.
11. McNulty C, Logan M, Donald IP, et al. Successful control of Clostridium difficile infection in an elderly care unit through use of a restrictive antibiotic policy. J Antimicrob Chemother 1997; 40:707-711.
12. Carling P, Fung T, Killion A, Terrin N, Barza M. Favorable impact of a multidisciplinary antibiotic management program conducted during 7 years. Infect Control Hosp Epidemiol 2003; 24:699-706.
13. Gerding DN, Johnson S, Peterson L, Mulligan ME, Silva J. Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol 1995; 16:459-477.
14. Briller P, Shank B, Lind L, et al. Moxifloxacin therapy as a risk factor for Clostridium difficile-associated disease during an outbreak: attempts to control a new epidemic strain. Infect Control Hosp Epidemiol 2007; 28:198-201.
15. Gaynes R, Rimland D, Killum E, et al. Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Clin Infect Dis 2004; 38:640-645.
16. McDonald LC, Coigard B, Dubberke E, et al. Recommendations for surveillance of Clostridium difficile-associated disease. Infect Control Hosp Epidemiol 2007; 28:140-145.
17. Rupnik M, Avesani V, Janc M, von Eichel-Streiber C, Delmee M. A novel toxinotyping scheme and correlation of toxinotypes with serogroups of Clostridium difficile isolates. J Clin Microbiol 1998; 36:2240-2247.
18. Stubbs S, Rupnik M, Gibert M, Brazier J, Duerden B, Popoff M. Production of actin-specific ADP-ribosyltransferase (binary toxin) by strains of Clostridium difficile. FEMS Microbiol Lett 2000; 186:307-312.
19. Killgore G, Thompson A, Johnson S, et al. Comparison of seven techniques for typing international epidemic strains of Clostridium difficile: restriction endonuclease analysis, pulsed-field gel electrphoresis, PCR-ribotyping, multilocus sequence typing, multilocus variable-number tandem-repeat analysis, amplified fragment length polymorphism, and surface layer protein A sequence typing. J Clin Microbiol 2008; 46:431-437.
20. McDonald LC, Owings M, Jernigan DB. Clostridium difficile infections in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis 2006; 12:409-415.
21. Chandler RE, Hedberg K, Cieslak PR. Clostrdium difficile-associated disease in Oregon: increasing incidence and hospital-level risk factors. Infect Control Hosp Epidemiol 2007; 28:116-122.
22. Adams DA, Riggs MM, Donskey CJ. Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic Clostridium difficile strains in the cecal contents of mice. Antimicrob Agents Chemother 2007; 51:2673-2678.
23. Siegel JD, Rhinehart E, Jackson M, Chiarello L. Guidelines for isolation precautions: preventing transmission of infectious agents in healthcare settings, June 2007. Healthcare Infection Control Practices Advisory Committee. Available at: http://www.cdc.gov/ncidod/dhqp/pdf/guidelines/Isolation2007.pdf Accessed March 10, 2008.
24. Climo MW, Isreal DS, Wong ES, Williams D, Coudron P, Markowitz SM. Hospital-wide restriction of clindamycin: effect on the incidence of Clostridium difficile-associated diarrhea and cost. Ann Intern Med 1998; 128:989-995.
25. Pear SM, Williamson TH, Bettin KM, Gerding DN, Galgiani JN. Decrease in nosocomial Clostridium difficile-associated diarrhea by restricting clindamycin use. Ann Intern Med 1994; 120:272-277.
26. Valiquette L, Cossette B, Garant M-P, Diab H, Pepin J. Impact of a reduction in the use of high-risk antibiotics on the course of an epidemic of Clostridium difficile-associated disease caused by the hypervirulent NAP1/027 strain. Clin Infect Dis 2007;45(Suppl 2):S112-S121.
27. Muto CA, Blank MK, Marsh JW, et al. Control of an outbreak of infection with the hypervirulent Clostrdium difficile BI strain in a university hospital using a comprehensive "bundle" approach. Clin Infect Dis 2007; 45:1266-1273.
28. Leonard J, Marshal JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 2007; 102:2047-2056.
29. Jump RLP, Pultz MJ, Donskey CJ. Vegetative Clostridium difficile survives in room air on moist surfaces and in gastric contents with reduced acidity: a potential mechanism to explain the association between proton pump inhibitors and C. difficile-associated diarrhea. Antimicrob Agents Chemother 2007; 51:2883-2887.
30. Dubberke ER, Reske KA, Yan Y, Olsen MA, McDonlad LC, Fraser VJ. Clostridium difficile-associated disease in a setting of endemicity: identification of novel risk factors. Clin Infect Dis 2007; 45:1543-1549.
31. Dubberke ER, Reske KA, Olsen MA, et al. Evaluation of Clostridium difficile-associated pressure as a risk factor for C. difficile-associated disease. Arch Intern Med 2007; 167:1092-1097.